Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Optinose Inc
(NQ:
OPTN
)
0.9265
-0.0052 (-0.56%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Optinose Inc
< Previous
1
2
Next >
Optinose Reports Second Quarter 2024 Financial Results and Recent Operational Highlights
August 08, 2024
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Announces Reporting Date for Second Quarter 2024 Financial Results
August 02, 2024
Conference Call and Webcast to be held August 8, 2024, at 8:00 a.m. Eastern Time
From
Optinose, Inc.
Via
GlobeNewswire
Expanded Access to XHANCE with Addition to National Commercial Formularies
June 27, 2024
From
Optinose, Inc.
Via
GlobeNewswire
Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
May 17, 2024
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights
May 14, 2024
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Announces Reporting Date for First Quarter 2024 Financial Results
May 10, 2024
Conference Call and Webcast to be held May 14, 2024, at 10:00 a.m. Eastern Time
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Announces $55 Million Registered Direct Offering
May 09, 2024
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million
April 25, 2024
Conference Call and Webcast to be held April 25, 2024, at 10:00 a.m. Eastern Time
From
Optinose, Inc.
Via
GlobeNewswire
Optinose to Present at the Needham Virtual Healthcare Conference
April 04, 2024
From
Optinose, Inc.
Via
GlobeNewswire
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
March 15, 2024
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
March 07, 2024
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results
February 29, 2024
Conference Call and Webcast to be held March 7, 2024, at 8:00 a.m. Eastern Time
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice
January 18, 2024
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE
December 06, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference
November 22, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Reports Third Quarter 2023 Financial Results and Operational Updates
November 09, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Announces Reporting Date for Third Quarter 2023 Financial Results
October 27, 2023
Conference Call and Webcast to be held November 9, 2023, at 8:00 a.m. Eastern Time
From
Optinose, Inc.
Via
GlobeNewswire
Optinose to Present at the 2023 Cantor Global Healthcare Conference
September 22, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Reports Second Quarter 2023 Financial Results and Operational Updates
August 10, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million
July 27, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 16, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Optinose to Present at the Jefferies Healthcare Conference
June 02, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Reports First Quarter 2023 Financial Results and Operational Updates
May 11, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE
May 04, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Announces Reporting Date for First Quarter 2023 Financial Results
May 01, 2023
Conference Call and Webcast to be held May 11, 2023, at 8:00 a.m. Eastern Time
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 18, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Optinose to Present at the Needham Virtual Healthcare Conference
April 12, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights
March 07, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Announces Reporting Date for Fourth Quarter 2022 Financial Results
February 28, 2023
Conference Call and Webcast to be held March 7, 2023 at 8:00 a.m. Eastern Time
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Submits Supplemental New Drug Application for XHANCE Label Expansion
February 21, 2023
From
Optinose, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.